<DOC>
	<DOCNO>NCT00415519</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy 60mg MCI-186 via intravenous drip day patient ALS whose severity classify grade III , base change revise ALS functional rating scale ( ALSFRS-R ) score 24 week administration double-blind , placebo-controlled manner . And addition , study perform examine safety MCI-186 ALS patient meet severity classification III .</brief_summary>
	<brief_title>Efficacy Safety Study MCI-186 Treatment Amyotrophic Lateral Sclerosis ( ALS ) Who Met Severity Classification III</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Phenylmethylpyrazolone</mesh_term>
	<mesh_term>Antipyrine</mesh_term>
	<criteria>Patients define `` definite ALS , '' `` probable ALS '' `` probablelaboratorysupported ALS , '' meet diagnostic criterion revise EL Escorial Airlie House . Patients take least one action eat meal , excrete , move oneself alone , need assistance everyday life . Patients whose progress condition 12 week administration meet requirement . Patients judge inadequate participate study physician , patient ' general condition deteriorate point need hospitalize severe hepatic disease , sever heart disease , sever renal disease , need administer antibiotic infection . Patients complain difficulty breathing cause deteriorate respiratory function . Patients complication Parkinson 's disease , schizophrenia , dementia , renal failure , severe complication , patient anamnesis hypersensitivity edaravone . Pregnant , lactating , probably pregnant patient , patient want become pregnant , patient agree contraception . Patients administer investigational product within 12 week consent , participate clinical trial present . In addition exclusion criterion , patient judge inadequate participate study physician .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Amyotrophic lateral sclerosis</keyword>
	<keyword>free radical scavenger</keyword>
</DOC>